Our results demonstrate that patients with mutations in BBS10 have significantly higher levels of C-peptide indicating insulin resistance, supporting the suggestion that they are at higher risk of cardiovascular disease than patients with mutations in BBS1. This evidence concerns the gene BBS1 and cardiovascular disorder.